Approved treatments
for PNH

Empaveli

Empaveli (pegcetacoplan) is a complement inhibitor approved for the treatment of adults with PNH. It’s given by under-the-skin injection and can be self-administered.

Learn more

Fabhalta

Fabhalta (iptacopan) is an oral therapy approved for adults with PNH, including those previously treated and those who have not received any prior treatment.

Learn more

PiaSky

PiaSky (crovalimab-akkz) is an injectable therapy approved for certain adults and adolescents ages 13 and older with PNH. It is approved for people who are new to complement inhibitor treatment as well as those switching from another complement inhibitor.

Learn more

Soliris

Soliris (eculizumab) is a monoclonal antibody that works to reduce the destruction of red blood cells in people with PNH. It was the first therapy approved to lessen blood cell destruction, a process known as hemolysis, in those with PNH.

Learn more

Ultomiris

Ultomiris (ravulizumab-cwvz) is a complement inhibitor that’s approved for the treatment of adults and children with PNH. It’s given by an into-the-vein infusion or an under-the-skin injection.

Learn more

Voydeya

Voydeya (danicopan) is an oral medication that’s approved as an add-on treatment to Ultomiris (ravulizumab) or Soliris (eculizumab) to help treat red blood cell destruction occurring outside blood vessels in adults with PNH.

Learn more